Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.59 |
| ▸ | NPY1R | P25929 | 8/20 | 0.59 |
| ▸ | NPY2R | P49146 | 5/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433292 | 0.95 | NPY4R (0.55) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL31433391 | 0.91 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL29783638 | 0.91 | NPY4R (0.49) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL31433365 | 0.90 | TFPI (0.54) | NPY4RNPY5RNPY1RNPY2RTFPI | |
| SCHEMBL28007642 | 0.87 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL29871918 | 0.86 | NPY4R (0.66) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL31433319 | 0.86 | IL23R (0.52) | NPY4RNPY5RNPY1RTFPI | |
| SCHEMBL3205643 | 0.85 | NPY4R (0.65) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL31433345 | 0.85 | NPBWR1 (0.63) | KISS1R | |
| SCHEMBL31279687 | 0.84 | NPY4R (0.60) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | NPY4R 1616/4885NPY5R 3645/4885NPY1R 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.